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BACKGROUND: The 2 closely related small GTPases, RHOC and RHOA, are involved in mammary gland carcinogenesis;
however, their specific roles in determining cancer cell adhesion and invasion have not been elucidated. METHODS: RHOA
and RHOC are highly homologous, thereby posing a major challenge to study their individual functions in cancer
cells. By selectively knocking down these proteins, we have been able to alternatively inhibit RHOC and RHOA, while
preserving expression of the other rho protein. Quantitative analyses of the growth patterns and invasion in the
aggressive estrogen receptor negative cell lines MDA-231 and SUM149 were carried out on collagen I and Matrigel
substrates. RESULTS: RHOC, and not RHOA, modulates surface expression and colocalization of a2 and b1 integrins in
MDA-MB-231 on collagen I. Neither RHOC or RHOA affected integrin expression in the inflammatory breast cancer
cell line SUM149, further highlighting the different regulation of adhesion and motility in inflammatory breast cancer.
CONCLUSIONS: This work shows that RHOC and RHOA play different roles in cell-matrix adhesion, motility, and
invasion of MDA-MB-231 and reaffirms the crucial role of RHOC-GTPase in inflammatory breast cancer cell invasion.
Cancer 2010;116(11 suppl):2768–82. VC 2010 American Cancer Society.
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RHOC and RHOA belong to the Ras superfamily of small GTPases. The protein sequences of RHOA and RHOC are
approximately 90% homologous, with the major divergence occurring at the carboxyl termini. In the human genome, the
RHOC gene (ARHC) contains fewer introns. This has led to the hypothesis that RHOCmay have originated as an incom-
plete duplication of the RHOA gene.1 Because the RHO proteins (A, B, C) are closely related to RAS oncogenes, their
roles in carcinogenesis have been studied extensively. Persistent activation of RHO transforms fibroblasts and RHO inhi-
bition abrogates oncogenic RAS-mediated transformation in these cells.2 In addition, it has been shown that RHO activa-
tion increases cell proliferation by downregulating the cyclin-dependent kinase inhibitors, p21WAF1 and p27KIP1.2 Unlike
the case of RAS, there are no known pathogenic mutations in the RHO genes.1 Biologically relevant aberrant levels of
RHO expression, however, are commonly found in many types of cancers. For example, RHOA overexpression has been
described in breast cancer, testicular germ-cell tumors, and colon cancer.3 Conversely, upregulation of RHOC is prevalent
in inflammatory breast cancer, pancreatic cancer, hepatocarcinoma, and melanoma, with a strong association between
expression levels and poor prognosis.4-10 Indeed, ectopic expression of RHOC in nontransformed immortalized breast
cells leads to a highly malignant phenotype.11
RHO proteins play prominent roles in regulating cytoskeletal organization, directional migration, and tumor cell
motility.12 RHO activation leads to F-actin stress fiber formation and the assembly of focal adhesion complexes.12 Within
the focal adhesion complexes, integrins interact specifically with extracellular matrix (ECM) components.12-15 Integrin
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engagement reciprocally activates the RHO proteins and
their downstream effectors.16 The functions of integrins
in tumorigenesis are extremely diverse because of the vari-
ety of combinations of integrin subunits and their over-
lapping spectrum of interactions with different types of
ECM.17 Although cancer cells are relatively anchorage-in-
dependent and can survive and proliferate without certain
ECM components, they are able to also modulate expres-
sion of different integrin subunits to support or enhance
proliferation, survival, and migration17.18-20
The a2b1 integrin, a collagen receptor in many
cell types, plays an important role in cell differentiation
and morphogenesis.21 The expression levels of the a2
subunit are altered in different stages of cell differentia-
tion.21 Expression of integrin a2 is stringently regulated
in the normal mammary gland: it is downregulated
during lactation and is elevated in the nonpregnant
gland.22 In poorly differentiated breast cancer cells,
endogenously induced expression of the a2 subunit
reduced their metastatic potential.23 Ablation of a2
expression by antisense a2 mRNA treatment altered
breast cell adhesion and motility on collagen.24 Overex-
pression of the a2 subunit in rhabdomyosarcoma cells
also rendered the cells invasive.25 Moreover, expression
of the a2 subunit was aberrantly elevated in in vitro
RAS-transformed mammary epithelial cells and osteo-
genic sarcoma cells.26 Tumor promoters 12-O-tetradec-
anoylphorbol 13-acetate (TPA) and okadaic acid (OA)
further enhanced a2 transcription in human osteosar-
coma cells and melanoma cells.27,28
The b1 subunit of the a2b1 integrin is by far the
best-studied integrin and a crucial subunit of many
ECM receptors. b1 receptor signaling is required for cell
proliferation, survival, and differentiation in normal
mammary gland development in vivo.29,30 Notably, b1
null mammary epithelial cells proliferate more slowly
than controls and express significantly higher levels of
p21Cip1, a cyclin-dependent kinase (CDK) inhibitor.30
In a transgenic mouse model of breast tumorigenesis, b1
was found to be essential for oncogenic transformation
and the maintenance of proliferative capacity in vivo.31
b1 signaling promoted the invasion and metastasis of
squamous cell carcinoma and RAS/MYC-transformed
fibroblasts.32,33 In addition, ablation of b1 in keratino-
cytes severely affected the orientation of the actin cyto-
skeleton and polarized migration required for cell
motility.34
In this study, we report that RHOC modulates the
expression and localization of the integrin a2 and b1 sub-
units in the breast cancer cell line MDA-MB-231. We
aimed to understand the molecular basis of the role of
RHOC and RHOA in motility and invasion of breast
cancer cells. After producing the crucial but challenging
cellular reagents that harbored siRNAs specific for either
RHOC or RHOA, we were able to show that RHOA
knockdown cells were more invasive and proliferative
than RHOC-RNAi–expressing cells. Moreover, the
RHOC knockdown cells failed to adhere to collagen I and
expressed low surface levels of a2 and b1 integrin subu-
nits, providing an explanation for their reduced motility
and invasiveness. Therefore, we conclude that RHOC
and RHOA are playing different roles in regulating
MDA-MB-231 motility and invasion through cell-matrix
adhesion.
MATERIALS AND METHODS
RNAi Design and Plasmid Construction
To stably express RNAi targeted to RHOA or RHOC,
the small interference (si)RNA expression vector, pSi-
lencer hygro (Ambion, Austin, Tex) was chosen in this
study. RNAi target sites (21 mer) on RHOA and RHOC
genomic sequences were selected using Ambion’s siRNA
target selection Web tool (http://www.ambion.com/tech-
lib/misc/siRNA_design.html). The candidate sequences
were validated by BLAST analysis (www.ncbi.nlm.nih.-
gov/BLAST) to eliminate the possibility of knockdown of
genes other than RHOA and RHOC. The selected target
sequences were incorporated separately into 55-60 nt
hairpin siRNA oligonucleotide pairs, which encode 19
mer hairpin sequences specific to the mRNA target, a
loop sequence separating the 2 complementary domains,
and a polythymidine tract to terminate transcription
(www.ambion.com/techlib/misc/psilencer_converter.
html).











TTTTTTGGAAA-30) were annealed onto HindIII-
BamHI digested pSilencer Hygro according to the
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manufacturer’s instructions. The negative control
scrambled siRNA (Ambion) on pSilencer was included in
this study as a negative control.
Cell Culture
SUM149 cells (http://www.asterand.com/Services/
RepositoryServices/149PT.asp) were cultured in Ham
F12 (Mediatech, Manassas, Va) supplemented with 5%
FBS (Invitrogen, Carlsbad, Calif), insulin and hydrocorti-
sone (Sigma, St. Louis, Mo) at 37C under 10% CO2.
MDA-MB-231 (American Type Culture Collection,
Manassas, Va) was cultured in MEM (Mediatech) supple-
mented with Earle salt, L-glutamine and 10% fetal bovine
serum (FBS; Invitrogen) at 37C under 10% CO2. The
plasmids described above were transfected into SUM149
orMDA-MB-231 using GeneJammer transfection reagent
(Stratagene, La Jolla, Calif). Stable transfectants were
developed as previously described35 and maintained in the
medium supplemented with 150 lg/mL Hygromycin
(Invitrogen).
Western Analysis
Cells were washed in cold phosphate-buffered saline
(PBS) and lysed in lysis buffer for RHOC (10% glycerol,
50 mM Tris pH 7.4, 100 mM NaCl, 1% NP-40, 2 mM
MgCl2, 1 lg/mL leupeptin, 1 lg/mL aprotinin, 1 mM
PMSF) or in RIPA buffer on ice for 5 minutes. After cen-
trifugation for 5 minutes at top speed at 4C, cleared
lysates were collected, electrophoresed onto SDS-PAGE
(60 lg of protein each lane), and transferred to polyvinyli-
dene fluoride (PVDF) membrane using a semidry appara-
tus (BioRad, Hercules, Calif). Western analysis was
performed as previously described35 with the anti-RHOC
rabbit polyclonal antibody (Santa Cruz Biotechnology,
Santa Cruz, Calif) at 1:2000 dilution, the anti-RHOA
mouse monoclonal antibody (Santa Cruz) at 1:1200 dilu-
tion, the anti-a2 polyclonal antibody (Santa Cruz) at
1:200 dilution, the anti-b1 polyclonal antibody (BD Bio-
science, Franklin Lakes, NJ) at 1:500 dilution, the anti-a5
polyclonal antibody (Santa Cruz) at 1:200 dilution, or
anti-b-actin goat antibody (Sigma) at 1:2000 dilution.
RHO Pulldown Assay
RHO pulldown assays were performed per manufac-
turer’s instructions (Upstate Charlottesville, Va). Cells
were cultured in 150 mm dishes to 85%-90% confluence.
The dishes were rinsed twice with ice-cold Tris-buffered
saline, and 0.5-1 mL of ice-cold Mg2þ lysis/wash buffer
(25 mMHEPES, pH 7.5, 150 mMNaCl, 1% Igepal CA-
630, 10 mM MgCl2, 1 mM EDTA, 2% glycerol, 10 lg/
mL aprotinin and 10 lg/mL leupeptin) was added to the
plates on ice. Cells were scraped off the plates using a cell
scraper. The lysates were transferred to eppendorf tubes
and incubated for 15 minutes at 4C with agitation. A
fraction of the lysate (250 lL) was incubated with 30 lg
of the GST-rhotekin agarose beads overnight at 4C with
agitation. The beads were spun down by brief centrifuga-
tion (14,000 rpm for 10 seconds) at 4C. The supernatant
was removed, and the beads were washed 3 times with 1X
Mg2þ lysis/wash buffer (0.5 mL) and then resuspended in
2XWestern buffer and boiled for 5 minutes. The superna-
tant was collected and loaded to an SDS-PAGE gel for
Western analysis with RHOA and RHOC.
Immunofluorescence Staining
of Cultured Cells
Cells were grown on collagen I-coated chamber slides for
24 hours and washed with PBS followed by fixation with
4% paraformaldehyde in PBS for 10 minutes. Fixed cells
were washed in PBS-glycine (10 mM) for 5 minutes, incu-
bated with 2% goat serum in PBS for 1 hr to block non-
specific binding, and permeabilized with 0.1% Triton X-
100 in PBS-2% goat serum. For stress fiber staining, fixed
cells were permeabilized with 0.1% Triton X-100 in PBS
for 5 minutes, incubated with 1:100 dilution of Alexa-
Fluor 568-conjugated phalloidin (Molecular Probes) for
15 minutes, and washed 3 times in PBS. To observe the
focal adhesion points, a 1:200 dilution of the anti-FAK
rabbit polyclonal antibody (Santa Cruz) was used as the
primary antibody and 1% bovine serum albumin (BSA)
was used as a blocking reagent in place of goat serum. For
double staining of integrins, a 1:1000 dilution of the anti-
a2 mouse monoclonal antibody (JBS2 clone; Chemicon,
Billerica, Mass), a 1:1000 dilution of the anti-a5 mouse
monoclonal antibody (NK1-Sam-1 clone; Chemicon), a
1:1000 dilution of the anti-b1 rat monoclonal antibody
(AIIB2, a kind gift from Dr. Lilli Petruzzelli, University
of Michigan), a 1:500 dilution of the anticofilin 2 rabbit
polyclonal antibody (Upstate), or a 1:1000 dilution of the
mouse IgG2a or IgG2b (Chemicon) in PBS-2% goat se-
rum were added to each slide and allowed to stain for
overnight at room temperature. The slides were subse-
quently washed 3 times in PBS-2% goat serum and
stained with 1:1000 dilution of Alexa Fluor 488-conju-
gated antirat secondary antibody (Molecular Probes) and
1:1000 dilution of Alexa Fluor 568-conjugated antimouse
secondary antibody (Molecular Probes), followed by 3
washes in PBS-2% goat serum. DAPI (40,6-diamidino-2-
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phenylindole; Molecular Probes) was used for nuclear
counterstaining. All the slides were mounted in Prolonged
Gold Antifade reagent (Molecular Probes) and observed
under an Olympus FV-500 Confocal Microscope (Olym-
pus, Melville, NY) at the Microscopy and Image Analysis
Laboratory at the University of Michigan Medical School
(CDBMIL).
Monolayer Growth Rate
Monolayer culture growth rate was determined by the
degree of conversion of 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) (Sigma) to a water-
insoluble formazan by viable cells.11 Five hundred cells in
200 mL of medium were plated in 96-well plates and
grown under normal conditions. At various time points,
cultured cells were treated with 40 mL of 5 mg/mL MTT
for 1 hour at 37C. The MTT-containing medium was
aspirated and 100 lL of dimethyl sulfoxide (DMSO)
(Sigma) were added to lyse the cells and solubilize the
formazan. Absorbance values of the lysates were
determined on a Dynatech MR 5000 microplate reader at
595 nm.
Random Motility Assay
Random cell motility was determined by using a motility
assay kit (Cellomics, Pittsburg, Pa). Cells were harvested,
washed with PBS, suspended in serum-free medium, and
plated on top of microscopic fluorescent beads evenly dis-
tributed on a well of a 96-well plate coated with collagen I
(BD Biocoat, Mississauga, Ontario, Canada). After a 24-
hour incubation period, cells were fixed, and areas of
clearing in the fluorescent bead field corresponding to
phagokinetic cell tracks were quantified using NIH Image
Version 1.63.
Boyden Chamber Invasion Assay
Invasion assays were performed on 24-well culture dishes
in accordance with manufacturer’s instructions (Chemi-
con). The inserts within each dish were equipped with a
polycarbonate membrane on the bottom coated with a
thin layer of extracellular matrix proteins (Matrigel,
Mississauga, Ontario, Canada). In brief, the inserts were
rehydrated in serum-free media. Cells were washed in
PBS and resuspended in serum-free medium at a concen-
tration of 5 105 cells/mL and 0.5 mL of cell suspension
was added to the insert. Wells in the culture dish were
filled with serum-containing medium. The dish was incu-
bated for 24 hours at 37C at 10% CO2. The cell suspen-
sion was aspirated and noninvasive cells were removed
from the insert using a cotton swab. The inserts were
bathed in the staining solution for 20 minutes and then
rinsed in water. Stained cells, which invaded through
Matrigel, were counted under an Olympus inverted
microscope.
Matrix Adhesion Assay
Adhesion assays were performed on 96-well culture strips
precoated with collagen I per manufacturer’s instructions
(Chemicon). The wells were rehydrated in serum-free
media. Cells were washed in PBS and resuspended in
serum-free medium supplemented with 0.1% BSA at a
concentration of 106 cells/mL, and 0.1 mL of cell suspen-
sion was added to each well. The strips were incubated for
1 hour at 37C at 10% CO2. The wells were aspirated,
washed 3 times in PBS, and stained with the staining solu-
tion (0.2% crystal violet in 10% ethanol) for 5 minutes.
Excess dye was removed by 3 washes of PBS and stained
cells were scored by dissolving the dye in 10% acetic acid
for ODmeasurement at 570 nm.
RESULTS
Development and Characterization of
SUM149 and MDA-MB-231 Clones Stably
Expressing RNAi Against RHOA or RHOC
To elucidate the roles of RHOA and RHOC in aggressive
breast cancers, we designed hairpin siRNAs (sequences
listed in the Materials andMethods section) to specifically
and selectively target RHOA or RHOC. As cellular
reagents, we chose to study the parental lines SUM149,
derived from an inflammatory breast cancer (IBC) speci-
men and MDA-MB-231 derived from an estrogen recep-
tor negative, metastatic breast cancer. The oligonucleotide
pairs of hairpin siRNA RNAi-150 and RNAi-428 for
RHOA, RNAi-121 and RNAi-280 for RHOC were
ligated into pSilencer-Hygro vector (Ambion). These vec-
tors were transfected into SUM149, an IBC cell line, and
MDA-MB-231, known as a highly aggressive, estrogen re-
ceptor-negative, non-IBC breast cancer cell line. The
hygromycin resistance marker in the vector allowed for
the selection of stable clones expressing RNAi. Western
analysis was used to identify hygromycin-resistant clones
with very low RHOA or RHOC expression. All the
RHOC knockdown clones of MDA-MB-231 were origi-
nally transfected with RNAi-121, while the SUM149 sub-
clones were RNAi-280 transfectants only. For further
characterization, we chose 2 stable RNAi clones against
RHOA and 2 against RHOC in each cell line. We have
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Figure 1. Expression of RHOA and RHOC in RHOC-siRNA–expressing clones of SUM149 and MDA-MB-231 is illustrated. (A,B) RHOC and
RHOA protein expression of the RHOC-siRNA-expressing clones was confirmed by Western analysis using the anti-RHOA monoclonal
antibody and anti-RHOC polyclonal antibody. Cleared lysates (50 lg of protein each) were electrophoresed onto SDS-PAGE and trans-
ferred to polyvinylidene fluoride membrane for Western analysis. The protein levels of b-actin were used as loading controls. (C,D) Protein
expression of RHOA and RHOC in RHOA-siRNA expressing clones of SUM149 and MDA-MB-231. (E,F) RHOA and RHOC activity in the
RHOA- or RHOC-knockdown cells. Cells were lysed and incubated with the GST-rhotekin RBD agarose beads overnight at 4C with agita-
tion. The beads were washed 3 times then resuspended in 2X Western buffer and boiled for 5 minutes. Approximately 1 of 3-1 of 4 of the
supernatant (equal to 700-800 lg of total protein) was loaded onto an SDS-PAGE gel forWestern analysis with RHOA and RHOC.
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confirmed that the stably transfected siRNA against
RHOA or RHOC effectively knocked down target pro-
tein expression (Fig. 1). Western analysis confirmed that
RHOC protein levels among the RHOC siRNA clones of
both breast cancer cell lines were 85% lower than in
untransfected and siRNA negative controls (Fig. 1A, 1B).
The siRNA knockdown of RHOCwas effective and selec-
tive in that it did not significantly affect RHOA expres-
sion in most cases (Fig. 1A, B, E, F). The RHOA protein
levels were either stable (Fig. 1B, E, F) or slightly lower
than the controls in the RHOC knockdown clones of
MDA-MB-231 (Fig. 1A). Conversely, we have also dem-
onstrated that our hairpin RHOA siRNA dramatically
reduced RHOA expression but did not significantly
decrease RHOC expression (Fig. 1C, D, E, F). We
observed that RHOC protein levels slightly increased in
the siRNA-RHOAMDA-MB-231 clones (Fig. 1C, E).
The SUM149 and MDA-MB-231 Clones Stably
Expressing RNAi Against RHOA or RHOC
Specifically Knockdown RHOA or
RHOC Activity
We expected that the knockdown clones with low expres-
sion levels of RHOA or RHOC would yield low activity
of RHOA or RHOC. The Rho pulldown assay (affinity
precipitation) was performed to demonstrate the activity
levels of RHOA and RHOC. In brief, these clones (1 for
each group) were expanded in 150 mm dishes, lysed, and
incubated with the RHO-binding domain (RBD) of rho-
tekin, a paradigm of a RHOC effector, immobilized to
agarose beads (Upstate). The active RHOA or RHOC
protein in a GTP-bound form could interact specifically
and tightly to rhotekin RBD during washes, and would be
released by boiling in Western sample buffer. For control
purpose, a fraction of the sample was subjected toWestern
analysis of RHOC and RHOA. The levels of active
RHOC in the siRNA-RHOC–expressing MDA-MB-231
clones decreased>30% compared with untransfected and
the siRNA negative controls (Fig. 1E), whereas the
RHOC-knockdown clone of SUM149 showed a 70%
decrease in active RHOC (Fig. 1F). As expected, the activ-
ity of RHOA remained constant in the siRNA-RHOC
clones compared with the controls (Fig. 1E, F). The
siRNA knockdown of RHOA in both lines effectively and
specifically decreased RHOA activity in comparison to
the control clones (Fig. 1E, F). Thus, we have confirmed
that the RHOA- or RHOC-knockdown clones contained
significantly lower levels of active RHOA or RHOC (Fig.
1E, F), respectively.
Stable Clones Expressing RNAi Against RHOC
or RHOA Show Reduced Invasion, Motility,
and Monolayer Growth Rate
Our initial hypothesis was that RHOA or RHOC knock-
down in cancer cells would decrease their proliferation
rate. Mammary epithelial cells stably transfected with
RHOC and constitutively active RHOC showed a 2-fold
increase in the monolayer growth assay as compared with
the vector-only controls.35 The results indicate that
RHOA and RHOC knockdown clones exhibit different
rates in MTT assays (Fig. 2A, B). SUM149 and MDA-
MB-231 expressing RHOC-siRNA grew very slowly, at a
rate that is 4-fold slower than untransfected and control
siRNA samples (Fig. 2A, B). In contrast, the specific
knockdown of RHOA did not affect cancer cell growth as
prominently as the RHOC knockdown (Fig. 2A, B).
These results suggest differential effects of RHOA and
RHOC on signaling to the cell cycle or time of passage
through the cycle.
Overexpression of RHOC in immortalized breast cells
is known to increase cell invasion and motility, 2 important
phenotypic parameters for quantifying the metastatic
potential of cancer cells in vitro.11,35 RHOA overexpression
was also observed in several breast cancer cell lines.3,36 In
this study, we proposed that decrease of RHOC or RHOA
below their regular levels in breast cancer cells would reduce
cell invasiveness and motility. Indeed, specific knockdown
of RHOA or RHOC rendered cancer cells less motile on
collagen I in random motility assays, as showed in Figure
2C days. It is worth noting that we found that RHOC
siRNA-expressing cells exhibited approximately 50% less
motility than their RHOA siRNA-expressing counterparts
(Fig. 2C, D). SUM149 and MDA231 cells expressing
RHOC or RHOA siRNA also showed significant decreases
of invasion in an invasion assay with Boyden chambers
coated with Matrigel (Fig. 2E, F). Because Matrigel com-
prises similar components as the basement membrane,
including laminin and collagen IV,37 our results support
that breast cancer cells with low RHOA or RHOC expres-
sion have reduced ability to penetrate the membrane.
RHOC-Silenced MDA-MB-231 Line Has Very
Low Adhesion on Collagen I
During the course of this work, we extensively investi-
gated the phenotypic differences between the RHOA-
and RHOC-knockdown clones in SUM149 and MDA-
MB-231. Because the knockdown clones exhibited low
motility on collagen I, we examined their adhesion on col-
lagen I using the cell-ECM adhesion assay (Chemicon).
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Figure 2. Characterization of malignant phenotypes in the small interference (si)RNA-expressing clones and the controls is illustrated.
(A,B) Monolayer growth rate of RHOC-knockdown or RHOA-knockdown clones is depicted. RHOC transfectants (500 cells), taken at Day
1, 3, 6, 8, and 10,were incubated with 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), solubilized in dimethyl sulfoxide
(DMSO), and measured absorbance at 595 nm. (C,D) The RHOC- or RHOA-specific knockdown clones showed decreased motility in ran-
dom motility assay. Cells were trypsinized, washed with PBS, and suspended in serum-free medium, and plated on top of a field of micro-
scopic fluorescent beads. After a 24-hour incubation period, cells were fixed, and areas of clearing in the fluorescent bead field
corresponding to phagokinetic cell tracks were quantified using NIH Image. (E,F) The RHOC- or RHOA-specific knockdown clones of
SUM149 and MDA-MB-231 had reduced invasion using Boyden chamber quantitative invasion assay. Cells were resuspended in serum-free
medium and seeded in the chemotaxis chamber coatedwith basement membrane extracellular matrix. Cells penetrating through the artifi-
cial basement membranes were stained and scored under a phase contrast microscope, or were treated with 10% acetic acid to elute the
dye for optical density (OD) readings at 560 nm. *p value versus untransfected control or the siRNA control.
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Indeed, the RHOC-knockdown MDA-MB-231 cells
adhered approximately 10-fold less than the controls on
collagen I (P value <.01) (Fig. 3A). In contrast, knocking
down of RHOA in MDA-MB-231 did not affect cell ad-
hesion as significantly as RHOC did, because adhesion
was lowered only to 20% of the control levels in the
RHOA-RNAi cells (Fig. 3A). This suggests that RHOA
and RHOC also play different roles in regulating cell ad-
hesion, motility, and invasion on collagen I. Interestingly,
no significant difference was observed between the
SUM149 RHOA-RNAi or RHOC-RNAi clones in their
adhesion on collagen I (Fig. 3B). This further suggests a
difference between mechanism of cell adhesion, motility,
and invasion in the 2 malignant breast cancer cell lines we
tested. On the basis of these results, we proposed that the
knockdown of RHOC in MDA-MB-231 compromised
the function of the collagen I receptor and resulted in
decreased collagen I adhesion and motility.
Stable Clones Expressing RNAi Against RHOC
or RHOA in MDA-MB-231 Show Reduced
Stress Fiber Assembly and Drastically
Fewer Focal Adhesions
RHOC overexpression in mammary epithelial cells induces
the assembly of actin filaments and the formation of multi-
ple focal adhesions.11,35 Given this finding, we proposed
that reduced RHO expression in highly motile cancer cells
would significantly decrease stress fiber formation as well as
the number and size of focal adhesions. The wildtype and
control-RNAi transfected cells cultured on collagen I-coated
glass slides displayed abundant stress fibers in star-like foci
across the cells38 (Fig. 4A, arrows). These cells had formed
extensive focal adhesions around the borders to support
their attachment to the matrix (Fig. 4B). Cells expressing
RHOA-siRNA showed fewer and thinner actin filaments
within the cytoplasm, but they lacked strong stress fibers
and focal adhesions (Fig. 4A, B). Also, some residual stellae
foci of the actin filaments were observed in these cells (Fig.
4A, arrows). In contrast, the RHOC-knockdown cells
showed some cortical actin staining with no stress fiber for-
mation and small focal adhesions (Fig. 4A, B). They failed
to display the star-like foci of actin filaments, suggesting
that these cells were less contractile (Fig. 4A). In summary,
we have found that RHOC-knockdown blocked the assem-
bly of stress fibers and contraction in MDA-MB-231 cells,
while silencing of the RHOA gene did not completely dis-
rupt F-actin assembly and contraction. These results further
suggest intrinsic differences between RHOA and RHOC
signaling in cytoskeleton assembly and cell contraction.
This is consistent with our findings in the adhesion assay.
RHOC Knockdown Impairs a2b1 Expression
and Surface Localization in MDA-MB-231
But Not in SUM149
The RHOC-knockdown MDA-MB-231 cells showed
very low adhesion to collagen I. Because the a2b1 integrin
is a major collagen receptor for luminal cells in mammary
glands, we sought to examine the protein expression levels
of the a2 and b1 subunits in the cell lysates. Expression of
a2 and b1 was downregulated by 50% in RHOA- and
RHOC-knockdown MDA-MB-231 clones (Fig. 5). The
a5 subunit, part of the fibronectin receptor a5b1, how-
ever, was largely unaffected in all the MDA-MB-231
Figure 3. Collagen I adhesion of the small interference
(si)RNA-expressing clones and the controls of MDA-MB-231
and SUM149 are depicted. (A, B) Adhesion assay on collagen
I of the MDA-MB-231 (A) and SUM149 clones (B) was con-
ducted using Cytomatrix strips (Chemicon). The adhered cells
were stained and scored using OD measurement at 570 nm.
*p: the RHOC values versus the siRNA control.
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sublines (Fig. 5). Conversely, the integrin expression pat-
terns of a2 and b1 in all the SUM149 clones were nearly
identical (Fig. 5). With the protein levels of b1 being
somewhat increased in the RHOA- and RHOC-knock-
down SUM149 clones (Fig. 5).
As the cell content of the individual integrin subu-
nits may not reflect the actual amount of functional integ-
rin receptors on the plasma membrane, we used
immunofluorescence staining of the a2 and b1 subunits
on the cell surface to detect the presence of presumed
functional a2b1 receptors (Fig. 6A). In the untransfected
MDA-MB-231 and control siRNA samples, we found
that the integrin subunits strongly colocalized on the cell
membrane in a ring-like pattern (Fig. 6A). The colocaliza-
tion is consistent with the model that activated and
engaged integrin receptors cluster together and interact
Figure 4. Stress fiber and focal adhesion formation of the small interference (si)RNA-expressing clones and the controls are
depicted. (A,B) Confocal microscopy of the siRNA-transfected MDA-MB-231 cells stained with rhodamine-phalloidin (A) or FAK
(B) to observe stress fibers and focal adhesion points. The star-like foci of stress fibers in the controls and the RHOA-knockdown
cells were marked with white arrows. Bar, 50 lm.
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with the ECM on the cell surface.17 The RHOA-knock-
down cells showed both weaker staining and membrane
colocalization of a2 and b1, at significantly lower levels
than the 2 control lines (Fig. 6A). In the RHOC-knock-
down line, the a2 and b1 staining was even lower and the
membrane localization was completely disrupted (Fig.
6A). We observed some a2 and b1 staining within the
cytoplasm (Fig. 6A). Conversely, the surface localization
of the a5 integrin showed no difference under any condi-
tions (Fig. 6B). The RHOC-knockdown cells showed
faint b1 staining, so consequently the colocalization of
a5b1 was not prominent (Fig. 6B).
In comparison to the MDA-MB-231 and siRNA-
RHOC cells and the SUM149 and siRNA-RHOA cells,
the RHOC-knockdown SUM149 cells showed no signifi-
cant change in cell adhesion on collagen I. We further
examined the immunofluoresence patterns of integrins
a2, a5, and b1 and found that their membrane localiza-
tion was nearly identical among all the SUM149 clones
(Fig. 7A, B). Thus, knockdown of RHOC in the
SUM149 IBC cells did not affect the expression or coloc-
alization of a2 and b1 in SUM149 (Fig. 7A). The control
staining with cofilin-1 and the isotype-matching mouse
IgGs was also performed in these lines, both showing very
low background staining (data not shown).
In conclusion, we observed that the major difference
between the RHOA- and RHOC-knockdown MDA-MB-
231 lines was their ability to adhere on collage I. Consistent
with this observation, we observed weak staining and mem-
brane localization of integrin a2 and b1 in RHOC-knock-
down cells, unlike the stronger staining and proper
colocalization of the integrin subunits found in RHOA-
knockdown cells. We conclude that RHOC, but not
RHOA, plays a major role on MDA-MB-231 cell adhesion
to collagen I. This work also suggested a difference between
the roles of RHOA and RHOC in motility and invasion on
collage I in the MDA-MB-231 line. In contrast, the protein
expression levels and membrane localization of integrin a2
and b1 on collage I were not significantly affected in all the
SUM149 lines, suggesting a different mechanism of inva-
sion in SUM149.
DISCUSSION
RHO GTPase activation and signaling is highly complex,
given the finding that RHO transduces signals to various
immediate downstream effectors via direct binding.
ROCK, CITRON, PKN, and RHOTEKIN are major
effectors that regulate cell morphology, actin cytoskeleton
assembly, gene expression, cell proliferation, and survival
downstream of their interaction with RHO.2 We sought
to delineate the difference in RHOA- and RHOC-de-
pendent signaling using RNA interference technology to
specifically knockdown the expression of each GTPase in
breast cancer cells. Compared with the well-studied
RHOA, RHOC function and signaling had remained
poorly understood. Evidence showed that RHOC
appeared to have higher affinity and specificity to ROCK
and CITRON than RHOA,39,40 thereby hinting that the
downstream RHOA phenotype may differ from RHOCs.
The activation of ROCK by RHOC leads to disruption of
adherens junctions.40 ROCK activation by RHO/RHOC
also contributed to increased cell motility, enhanced F-
actin assembly, and carcinogenesis through activation of
the LIM kinase-cofilin pathway.16,40-43 Consistent with
our results, Hakem and colleagues44 recently established
the RHOC-knockdown transgenic mice, which showed
no significant defect in embryogenesis, development, and
tumor initiation by polyoma virus middle T antigen.
However, the RHOC mice developed fewer instances
of lung metastases of significantly smaller size. The
authors hypothesized that RHOA is involved in tumor
initiation and RHOC is crucial for tumor metastasis.44
In an attempt to identify molecules involved in
RHOC downstream signaling, we had previously per-
formed microarray analysis of RHOC-overexpressing
MCF10A cells.35 We found that overexpression of
RHOC significantly increased the mRNA levels of cyclin
D1, fibronectin, VEGF-C, caveolin-2, and CXCL1, and
also decreased the levels of IGFBP-2.35 These gene prod-
ucts, which are involved in cell cycle (cyclin D1), cell-
Figure 5. Integrin a2 and b1 expression in the whole cell
lysates of MDA-MB-231 clones is depicted. Protein levels of
integrins a2, a5, b1, and actin (loading control) were measured
using 50 lg of lysates in RIPA buffer. Polyclonal antibodies
against a2, a5, and b1 were used for the Western analysis.
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Figure 6. Immunofluorescence analysis of a2 and b1 integrins in the small interference (si)RNA-expressing MDA-MB-231 clones
and controls is depicted. (A,B) Confocal microscopy of the RHOC- or RHOA-siRNA expressing MDA-MB-231 clones costained
with anti-a2 and anti-b1 monoclonal antibodies (A), or with anti-a5 and anti-b1 monoclonal antibodies (B). Bar, 10 lm.
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matrix adhesion (fibronectin, caveolin-2), and angiogenesis
(CXCL1 and VEGF-C), can contribute to the invasive,
angiogenic, and motile phenotype of RHOC-overexpress-
ing breast cells. Of particular interest is the role of RHOC
in the regulation of cell-matrix adhesion, because one of
the key functions of the RHO proteins is to respond to
matrix adhesion signals relayed by integrins by promoting
the assembly of focal adhesions and stress fibers.12
In this study, we sought to advance our understanding
of signaling by RHOA and RHOC in MDA-MB-231 and
SUM149, both estrogen receptor negative and poorly dif-
ferentiated breast cancer cell lines, with very different clini-
cal phenotypes: SUM149 is an inflammatory breast cancer
cell line, whereas MDA231 is an aggressive non-IBC cell
line. Knockdown of RHOA and RHOC in these 2 lines
greatly reduced their metastatic phenotypic features, includ-
ing proliferation, motility on collagen, and invasion into
Matrigel. These results correlate well with previous findings
for MDA-MB-231 cells.45 In SUM159, a cell line from an
anaplastic breast carcinoma, Simpson et al concluded that
RHOA knockdown inhibited its metastatic phenotypes
instead of RHOC.46 Unless SUM159 is not representative
of our findings because of its own particular genetic altera-
tions, his result is not in agreement with our data and that
of Hakem et al. In our hands, RHOC-specific knockdown
appeared to have a quantitatively stronger effect in reducing
motility (P< .0001), proliferation (P< .001), and invasion
(P< .001), recapitulating the in vivo results.44
Our data also show that RHOC knockdown
decreases surface expression and colocalization of the
Figure 7. Immunofluorescence analysis of a2 and b1 integrins in the small interference (si)RNA-expressing SUM149 clones and
controls is depicted. (A,B) Confocal microscopy of the RHOC- or RHOA-siRNA expressing SUM149 clones costained with anti-a2
and anti-b1 antibodies (A), or with anti-a5 and anti-b1 antibodies (B). Bar, 10 lm.
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integrin a2 and b1 subunits in MDA-MB-231, a poorly
differentiated breast cancer line. Conversely, Zutter at al
reported that forced expression of a2 in an a2 null, poorly
differentiated breast cancer line Mm5MT reduced its
metastatic potential.23 At the first glance, our result
appears to be inconsistent with the finding of Zutter et al.
However, because of the pleiotropic effects of RHOC sig-
naling, decreased expression of a2 and b1 by RHOC
silencing is unlikely to be the sole mechanism leading to
the reduction of MDA-MB-231 invasiveness. Indeed, we
recently found that the RHOC-knockdown MDA-MB-
231 cells displayed organized structures containing ZO-1,
a tight junction marker, and bore a striking resemblance
to the nontumorigenic MCF10A breast cells (Wu M,
unpublished observations). This result strongly suggests
that RHOC regulates not only cell-matrix adhesion but
also cell-cell adhesion in the metastatic cascade.
Cell-matrix adhesion is crucial in several functions
that comprise the metastatic process, such as local inva-
sion, angiogenesis and colonization of distant sites by tu-
mor metastasis.47 Downregulation of integrin subunits
contributes to a reduction of cell adhesion to the integrin-
specific extracellular matrix. RHOC-knockdown MDA-
MB-231 cells adhered very poorly on collagen I, a major
ECM in interstitial matrix and bones. In addition, these
cells did not move on collagen I-coated wells. RHOC-
silenced cells had very weak a2b1 colocalization and focal
adhesion, correlating with their low adhesion and motility
on collagen. Indeed, other groups have shown that in
prostate cancer, elevated levels of RHOC enhance colla-
gen I-a2b1 signaling and promote tumor metastasis to
bone matrix, which contains abundant collagen I.48,49
In integrin-matrix signaling, the surface amount,
affinity, and avidity of the given integrin subunits is regu-
lated by growth factor receptor pathways, RAS-MAPK
pathway, and RHO pathway.50 Recently, the oncogenic
RAS-MAPK pathway was identified as an activator of
RHOA, capable of activating the b1 integrin through
FRA-1, a target of the MAPK cascade.51 Crosstalk and/or
feedback between the RAS and RHO pathways also
enhance cell motility and proliferation.52,53 In the breast
cancer cell line T74D, a2b1- instead of a5b1 mediated
cell motility was selectively enhanced by R-RAS and phos-
phatidylinositol 3-kinase (PI3-K).54 In our work, we
found that RHOC knockdown decreased total protein
levels of the integrin a2 subunit and abolished its surface
localization. Expression of a2 is regulated by the 2 onco-
genic Ras isoforms, H-RAS and K-RAS,26,28,55 suggesting
that RAS-RHOC crosstalk/feedback may play a role in
regulating the expression levels of the a2 integrin. This
hypothesis is further supported by our previous result that
RHOC overexpression in mammary epithelial cells trig-
gered activation of the MAPK pathway responsible for
motility, invasion and production of angiogenic factors.56
In conclusion, our data defines the role of RHOC as a
unique and dominant force in the modulation of adhesion
and phenotypic metastatic features in breast cancer. We
propose the RAS-RHOC crosstalk/feedback is the possi-
ble mechanism in the regulation of cell-matrix adhesion
and integrin signaling of MDA-MB-231.
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